Related Experiment Video
Updated: Feb 11, 2026

Mass Production of Genetically Modified Aedes aegypti for Field Releases in Brazil
Published on: January 4, 2014
Consideraciones Regulatorias sobre Productos Biológicos en Brasil
1State University of Rio de Janeiro and Latin American Center for Biological Research (CLAPBio), Rio de Janeiro, Brazil.
Abstract:
Biosimilars are biologics developed to compete with originator biologics that have been on the market for a long time and lost their patent and market protection. The WHO guidelines on evaluation of Biosimilars provide clear guidance for regulators on how to develop and gain approval for these products. The aim of this paper is to inform of the current status of development in regulation of Biosimilars in Brazil according WHO Guidelines. The result of the comparison shows the Brazilian regulation conflicts with the principles of the WHO guidelines.
Related Concept Videos
Cis-regulatory Sequences
Cis-regulatory Sequences
Drug Products: Biologics, Biosimilars and Interchangeables
What is Conservation Biology?
Design Consideration
The factor of safety is another key...
Tensile Strength Considerations of Concrete
The dimensions and shape of a concrete specimen...

